WHO plans special meeting on 26th October to discuss COVAXIN approval

According to news agency, Chief Scientist of the health organization Soumya Swaminathan told that a meeting of the Technical Advisory Group will be held on October 26 to consider the EUL (Emergency Use List) for Covaxin.

Yogita

YogitaBy Yogita

Published on 18 Oct 2021 12:45 PM GMT

World Health Organization, WHO
X
PC: Social Media
  • Whatsapp
  • Telegram
  • Linkedin
  • Print
  • koo
  • Whatsapp
  • Telegram
  • Linkedin
  • Print
  • koo
  • Whatsapp
  • Telegram
  • Linkedin
  • Print
  • koo

Mumbai: The World Health Organization (WHO) is going to hold an important meeting on 26 October. In this, a decision can be taken on the emergency use of India's indigenous corona vaccine Covaxin.

According to news agency, Chief Scientist of the health organization Soumya Swaminathan told that a meeting of the Technical Advisory Group will be held on October 26 to consider the EUL (Emergency Use List) for Covaxin. India is working closely with Biotech to complete the WHO dossier.

So far six vaccines have been approved

The World Health Organization has approved only six COVID-19 vaccines so far. These include- Pfizer-BioNtech, Johnson & Johnson (J&J), Oxford-AstraZeneca, Moderna, Sinopharm and Sinovac Vaccines. According to the report, the EUL is a risk-based process that considers unlicensed vaccines for evaluation and listing. The process also includes clinical and in-vitro diagnostics to accelerate the availability of vaccines to people affected by a certain public health emergency.

Recently, the subject expert committee recommended the use of Covaxin in India for people aged two to 18 years. However, a few days later, the central government made it clear that experts are still considering the final approval for the Covaxin vaccine being prepared for children between the ages of two to 18 years. The vaccine is being evaluated.

Trial conducted in three phases

Covaxin has had to go through a long trial. Bharat Biotech had completed the trial in three phases for the under 18 age group. Phase II and III trials were completed in September. After this, Bharat Biotech's process of getting Covaxin is in the final stages. On Tuesday, suddenly the news of its approval started running in the media, but after some time the government had made it clear that the process of approval was going on. The matter is under consideration of the expert committee.

Stay tuned with the newstrack to get fastest updates. Click @englishnewstrack to follow us on Facebook and @newstrackmedia to follow on Twitter.

Yogita

Yogita

She covers current News topics, keeps the audience updated with Buzz around the world.

Next Story